Glyburide (Glibenclamide)

Table of contents

  • Brand Names
  • Drug Combinations
  • Chemistry
  • Pharmacologic Category
  • Mechanism of Action
  • Therapeutic Use
  • Unlabeled Use
  • Pregnancy and Lactation Implications
  • Contraindications
  • Warnings and Precautions
  • Adverse Reactions
  • Toxicological Effects
  • Caution and personalized dose adjustment in patients with the following genotypes
  • Other genes that may be involved
  • Substrate of
  • Inhibits
  • Drug Interactions
  • Nutrition/Nutraceutical Interactions
  • Dosage
  • Pharmacokinetics and Pharmacodynamics
  • Special Considerations

Brand Names


Austria: Daonil, Euglucon, Glibenclamid, Glucobene, Normoglucon; Belgium: Bevoren, Daonil, Euglucon; Bulgaria: Glibenclamide, Maninil; Cyprus: Daonil, Deroctyl, Glybesin, Gritisol; Czech Republic: Glucobene, Maninil; Denmark: Daonil, Hexaglucon; Finland: Euglamin, Euglucon, Origlucon; France: Daonil, Glibenclamide, Hemi-Daonil, Miglucan; Germany: Euglucon, Glib, Gliben, Glibenbeta, Glibenclamid, Glibendoc, Glukovital, Humedia, Maninil, Semi-Euglucon; Greece: Asugrin, Daonil, Deroctyl, Diabefar, Euglykon, Ikaton, Ozepal; Hungary: Gilemal, Glucobene; Ireland: Daonil, Glibenclamide, Semi-Daonil; Italy: Daonil, Euglucon, Gliben, Gliboral; Lithuania: Maninil; Luxembourg: Bevoren, Daonil, Euglucon, Glibenclamid, Glibenhexal; Malta: Daonil, Gritisol, Glibenclamide; Netherlands: Glibenclamide; Poland: Euclamin; Portugal: Daonil, Glibenclamida, Semi-Daonil; Romania: Glibenclamid, Maninil; Slovakia: Glucobene, Maninil; Slovenia: Daonil; Spain: Daonil, Euglucon; UK: Glibenclamide.

North America

Canada: Diabeta, Euglucon, Glyburide, Med-Glybe; USA: Diabeta, Glyburide, Glynase.

Latin America

Argentina: Benclamid, Broi, Daonil, Diabe Pass, Diabemin, Dismiben, Euglucon, Gardoton, Glaturin, Glibemida, Glibenclamida, Glidanil, Gliptid, Glitral, Pira, Siruc; Brazil: Aglucil, Clamiben, Daonil, Diaben, Diabexil, Euglucon, Glibenclamida, Glibenclamon, Glibendiab, Glicamin, Glionil, Lisaglucon; Mexico: Abuglib, Apogly, Biojara, Biostin, Daonil, Dibetid, Diglexol, Euglucon, Gadinor, Glemicid, Glibenclamida, Glibenil, Glibenval, Glicavin, Glicoxem, Glifarcal, Glipar, Glucal, Glucoven, Insusym, Mibeclag, Norboral, Ocrix, Reglusan.

Drug combinations

Glyburide and Metformin


Glyburide: C~23~H~28~ClN~3~O~5~S. Mw: 494.00. (1) Benzamide, 5-chloro-N-[2-[4-[[[(cyclohexylamino)carbonyl]amino]sulfonyl]phenyl]ethyl]-2-methoxy-; (2) 1-[[p-[2-(5-Chloro-o-anisamido)ethyl]phenyl]sulfonyl]-3-cyclohexylurea. CAS-10238-21-8 (1969).

Pharmacologic Category

Antidiabetic Agents; Sulfonylureas. (ATC-Code: A10BB01).

Mechanism of action

Stimulates secretion of endogenous insulin from β-cells of pancreas. Lowers blood glucose concentration in diabetic and nondiabetic individuals. During prolonged administration, extrapancreatic effects (e.g. enhanced peripheral sensitivity to insulin, reduction of basal hepatic glucose production) contribute to hypoglycemic action.

Therapeutic use

Management of type 2 diabetes mellitus (non-insulin-dependent, NIDDM). Alternative therapy in some type 2 diabetic patients being treated with insulin. Useful in combination with insulin therapy to improve glycemic control and/or decrease insulin dosage in some type 2 diabetic patients.

Pregnancy and lactiation implications

Nonteratogenic effects such as hypoglycemia in neonate associated with maternal glyburide use. Use of oral agents generally not recommended as routine management of type 2 diabetes mellitus during pregnancy. Insulin is considered drug of choice for control of diabetes mellitus during pregnancy. Use caution during lactation since hypoglycemia might occur in a nursing infant exposed to a sulfonylurea via breast milk.

Unlabeled use

Alternative to insulin in women for treatment of gestational diabetes mellitus (GDM)(11-33 weeks gestation).


Hypersensitivity to glyburide, any component of the formulation, or other sulfonamides. Type 1 diabetes mellitus (insulin-dependent, IDDM), diabetic ketoacidosis. Concurrent use with bosentan.

Warnings and precautions

Oral hypoglycemic drugs may be associated with increased cardiovascular mortality. Possible allergic skin reaction (e.g. erythema, pruritus, urticaria, morbilliform or maculopapular eruptions). Angioedema, arthralgia, myalgia, and vasculitis reported. Severe, occasionally fatal, hypoglycemia reported. Possible loss of glycemic control during periods of stress (e.g. fever, infection, surgery, trauma). Use with caution in geriatric patients and in renal or hepatic impairment (increased risk of hypoglycemia).



Legal Notice
Privacy Policy
Cookie Policy


Phone: +34-981-780505
Location: Sta Marta de, C. P. Babío, S/N, 15165 Bergondo, A Coruña

Copyright © 2023 WAGEM

Add to cart